Pergamon

Tetrahedron Letters 40 (1999) 6455–6459

TETRAHEDRON LETTERS

Clavirins, a new type of marine oxylipins with growth-inhibitory activity from the Okinawan soft coral, *Clavularia viridis*

Makoto Iwashima, Katsumi Okamoto and Kazuo Iguchi *

School of Life Science, Tokyo University of Pharmacy and Life Science, Horinouchi, Hachioji, Tokyo 192-0392, Japan

Received 27 May 1999; revised 24 June 1999; accepted 25 June 1999

Abstract

Two new marine carbocyclic oxylipins, clavirin I (**1**) and II (**2**), were isolated from the Okinawan soft coral, *Clavularia viridis*. Their structures containing unique α-side chains were determined, based on spectroscopic analysis and stereoselective total synthesis. Clavirins showed growth-inhibitory activity toward HeLa S3 cells.

The Okinawan soft coral, *Clavularia viridis* Quoy and Gaimard (class Anthozoa, subclass Octocorallia, order Stolonifera), contains numerous structurally unique antitumor prostanoids such as clavulones[1] and cytotoxic steroids.[2] During the course of our study on minor chemical congeners of the prostanoids from *C. viridis*,[3] two novel carbocyclic oxylipins,[4] clavirin I (**1**) and clavirin II (**2**), were discovered. These oxylipins showed growth-inhibitory activity toward Hela S3 at 1 μg/ml. This paper describes the isolation and structure determination of clavirins. Their chemical structures, including the absolute configuration, were determined based on spectroscopic analysis and stereoselective total syntheses of **1** and **2** from 4-alkoxy-2-cyclopentenone. Clavirins have proved to be a new type of clavulone-related oxylipins containing short α-side chains with a terminal aldehyde.



clavirin I (**1**)



clavirin II (**2**)

Wet specimens of *C. viridis* (17.1 kg), collected on the coral reef of Ishigaki Island (Okinawa, Japan) in December 1995, were immersed in methanol. The methanol extract (644.0 g) was partitioned between ethyl acetate (EtOAc) and H_2O to afford an EtOAc-soluble portion (123.5 g). The EtOAc-soluble portion (50.0 g) was chromatographed on a silica gel column by elution with hexane, hexane–EtOAc (from 10:1 to 1:1), EtOAc, and MeOH, in turn, to afford nine fractions. Compounds **1** {colorless oil, 2.2 mg, $[\alpha]_D^{25}$

* Corresponding author.

0040-4039/99/$ - see front matter
PII: S0040-4039(99)01285-X

Table 1
NMR Data for Clavirins I (1) and II (2)*

	1		2	
No	^{13}C	^{1}H	^{13}C	^{1}H
1	191.7 (CH)	10.79 (1H, d, 7.6)	190.6 (CH)	10.33 (1H, d, 8.0)
2	129.9 (CH)	6.21 (1H, d, 7.6)	125.6 (CH)	6.53 (1H, d, 8.0)
3	150.2 (C)		149.4 (C)	
4	192.9 (C)		192.5 (C)	
5	136.1 (CH)#	6.49 (1H, d, 6.2)	136.5 (CH)	6.54 (1H, d, 6.2)
6	158.4 (CH)	7.56 (1H, d, 6.2)	159.3 (CH)	7.65 (1H, d, 6.2)
7	83.5 (C)		84.4 (C)	
8	36.0 (CH_2)	2.77 (1H, dd, 7.4, 14.6)	37.3 (CH_2)	2.91 (1H, dd, 7.5, 14.5)
		2.68 (1H, dd, 7.7, 14.6)		2.88 (1H, dd, 7.1, 14.5)
9	120.1 (CH)	5.59 (1H, ddd, 7.4, 7.7, 10.9)	120.1 (CH)	5.62 (1H, ddd, 7.1, 7.5, 10.9)
10	136.0 (CH)#	5.23 (1H, dt, 7.1, 10.9)	134.8 (CH)	5.23 (1H, ddd, 1.6, 7.2, 10.9)
11	27.4 (CH_2)	1.96 (2H, br q, 7.1)	27.5 (CH_2)	1.95 (2H, br q, 7.2)
12	29.0 (CH_2)	1.20-1.36 (2H, m)	28.9 (CH_2)	1.20-1.40 (2H, m)
13	31.4 (CH_2)	1.20-1.36 (2H, m)	31.4 (CH_2)	1.20-1.40 (2H, m)
14	22.5 (CH_2)	1.20-1.36 (2H, m)	22.5 (CH_2)	1.20-1.40 (2H, m)
15	14.0 (CH_3)	0.88 (3H, t, 7.1)	14.0 (CH_3)	0.88 (3H, t, 7.1)
$CH_3\underline{C}O$	169.5 (C)		169.2 (C)	
$\underline{C}H_3CO$	21.3 (CH_3)	2.05 (3H, s)	21.3 (CH_3)	2.09 (3H, s)

* ^{1}H; 500 MHz in $CDCl_3$. J in Hz. ^{13}C; 125 MHz in $CDCl_3$.
# Values in the column are interchangeable. Assignments of the ^{13}C and ^{1}H signals were made based on HMQC.

$-17.1°$ (c 0.48, $CHCl_3$)} and **2** {colorless oil, 2.5 mg, $[\alpha]_D^{25}$ $-33.7°$ (c 0.43, $CHCl_3$)} from the fifth fraction [eluted with hexane–EtOAc (2:1)] were isolated in addition to clavulones by separation using flash column chromatography, medium-pressure liquid chromatography (MPLC), and HPLC.

The molecular formula of clavirin I (**1**) was assigned as $C_{17}H_{22}O_4$ by the combination of HREIMS [found: 230.1298; calcd: 230.1307 $(M-CH_3CO_2H)^+$] and ^{13}C NMR analysis. All 17 carbons appeared in the ^{13}C NMR spectrum of **1** (Table 1). DEPT indicated two methyls, five sp^3 methylenes, six sp^2 methines including one aldehyde, and four quaternary carbons containing two carbonyls. The IR, ^{1}H NMR (Table 1) and ^{13}C NMR spectra of **1** showed the presence of a conjugated cyclopentenone [IR 1714, 1682 cm^{-1}, δ_H 6.49 (1H, d), 7.56 (1H, d) ppm, δ_C 136.1 (CH), 158.4 (CH), 192.9 (C=O) ppm], a conjugated aldehyde [IR 1682 cm^{-1}, δ_H 6.21 (1H, d), 10.79 (1H, d) ppm, δ_C 129.9 (CH), 150.2 (C), 191.7 (CHO) ppm], an acetoxyl [IR 1735, 1227 cm^{-1}, δ_H 2.05 (3H, s) ppm, δ_C 21.3 (CH_3), 169.5 (C=O) ppm], and a disubstituted olefin [δ_H 5.23 (1H, dt), 5.59 (1H, ddd) ppm, δ_C 120.1 (CH), 136.0 (CH) ppm]. Sequential ^{1}H–^{1}H correlations between H-1 and H-2, H-5 and H-6, and from H-8 to H-11 were observed in ^{1}H–^{1}H COSY spectra. HMBC between H-2 and C-4, H-5 and C-3, H-6 and C-7, and H-8 and C-7 revealed carbon–carbon connections around three quaternary carbons (C-3, C-4 and C-7). These spectroscopic findings led to the gross structure of clavirin I (**1**). The Z stereochemistry of the disubstituted olefin in the ω-side chain was indicated by the coupling constant of the olefinic protons ($J_{9,10}$=10.9 Hz). The Z stereochemistry of the trisubstituted olefin in the short α-side chain was determined by the following evidence: the chemical shift value of H-1, the terminal aldehyde proton at δ 10.79, shifts much downfield due to the deshielding effect by C-4 carbonyl, however, the H-2 proton at δ 6.21 receives no such neighboring effect. The nuclear Overhauser effect between H-2 and H-8 observed in NOESY of **1** supported this stereochemistry. The absolute configuration at C-7 could not be confirmed by spectroscopic analyses.

Clavirin II (**2**) was found to have the molecular formula, $C_{17}H_{22}O_4$, the same as that for **1** by both HREIMS and ^{13}C NMR analyses. The ^{1}H and ^{13}C NMR spectra of **2** (Table 1) were quite similar to those of **1**, except for the signals assigned to the α-side chain. The chemical shift value in the ^{1}H NMR

spectrum of H-2 at δ 6.53 (1H, d) slides downfield due to the C-4 carbonyl deshielding, and H-1 at δ 10.33 (1H, d) shifts upfield compared to that of **1**, thus confirming the *E* stereochemistry of the trisubstituted olefin.

An answer to the remaining question in **1** and **2** on the absolute configuration at the C-7 chiral center bearing an oxygen function, corresponding to C-12 in clavulones, was important for not only determining the stereostructure but also understanding the biosynthesis of these oxylipins in *C. viridis*. In spite of the opposite absolute configuration, clavulones with 12*S* tertiary acetate and chlorovulones,[5] chlorinated antitumor marine prostanoids with 12*R* tertiary alcohol, were both found from the same organism, *C. viridis*.

The absolute configuration of **1** was determined from the results of the following total synthesis. Because of the presence of a tertiary acetate at C-7 which suggested **1** to be biosynthesized from clavulone itself or clavulone-type oxylipin, (*S*)-**1** was first chosen for the total synthesis. The synthetic outline for (*S*)-**1** consists of the preparation of the optically pure 4-alkoxy-2-cyclopentenone derivative with the ω-side chain, such as **7** in Scheme 1, followed by construction of the α-side chain using aldol condensation with (+)-glyceraldehyde acetonide. The compound **7** has already been reported for the stereoselective total synthesis of clavulones from (*S*)-4-hydroxy-2-cyclopentenone **a** through an intermediate **b**.[1c] During the crucial Claisen condensation, the proton at chiral C-4 bearing a secondary alcohol was found to be partially deprotonated with the generating lithium enolate at –78°C (Fig. 1).[6] The report indicates **7** could not be obtained in 100% ee by using this method. In order to unambiguously determine the absolute configuration of **1**, we decided to execute the new diastereomer-separation strategy, which involves the 1,2-addition to (±)-4-alkoxy-2-cyclopentenone with lithium enolate of (–)-acetoxymenthane to obtain the menthyl esters as a mixture of diastereomers, followed by HPLC separation to afford a reliable compound for the optical purity. This method provides an advantage to prepare the antipodal (*R*)-**1** such as chlorovulone-type oxylipins.



Figure 1.



Scheme 1. Reagents: (A) (–)-Menthyl-OAc, LDA, –78°C. The mixture of **4** and **5** was separated by recycling HPLC. (B) (1) TBSOTf, 2,6-lutidine, 92%; (2) DIBAL, –78°C, 81%; (3) hexyltriphenylphosphonium bromide, BuLi, HMPA, –50°C, 98%. (C) (1) Li, liq. NH_3, EtOH, –33°C, 77%; (2) CrO_3, H_2SO_4, 98%; (3) TBAF, 83%. (D) (1) TMSCl, iPr_2NEt, DMAP, 92%; (2) LiHMDS, –78°C, then (+)-glyceraldehyde acetonide, 76% (four diastereomers); (3) AcOH–H_2O; (4) Ac_2O, pyridine, DMAP. (E) (1) AcOH–H_2O, 40°C; (2) $NaIO_4$, 0°C

The synthesis was performed starting from the known cyclopentenone (±)-**3** prepared from cumene hydroperoxide in three steps.[7] Stereoselective Claisen condensation of (±)-**3** gave diastereomeric menthyl esters. After separation of two minor diastereomers (6% yield) by column chromatography, the desired two major esters were purified by recycled HPLC to obtain **4** ($[\alpha]_D^{25}$ −54.7°, 45% yield) and **5** ($[\alpha]_D^{25}$ −20.4°, 45% yield), respectively. The compound **4** showed a slightly shorter retention time in HPLC. The relative stereochemistry of each compound was confirmed by NOEs between protons at H-4 and H-8, corresponding to clavirin's numbering, but the absolute configurations were not determined at this stage because the known compound **7** was present in the next several steps. Further transformations were carried out for **4**; TBS protection, DIBAL reduction, and Wittig olefination provided **6** (three steps, 73% yield). The key intermediate **7**[8] was prepared in three standard steps (63% yield). The optical purity of **7** showed more than 99% ee by chiral HPLC analysis. All the spectral data of **7** were essentially identical to those of the known clavulone intermediate.[1c,8] According to these results, the stereo-structures of **4** and **5** as well as the other synthetic intermediates from **4** to **7** were automatically determined as shown in Scheme 1. The construction of the α-side chain was carried out by the following reaction sequence. After TMS protection of the tertiary alcohol (92% yield), the aldol coupling with the (+)-glyceraldehyde acetonide gave four diastereomeric aldols (76% yield). The mixture of the diastereomers was treated with acetic acid–H_2O to remove TMS, and then acetylation of the diol with acetic anhydride and catalytic amount of 4-dimethylaminopyridine in pyridine, in which β-elimination occurred simultaneously, gave cross-conjugated enones **8** (30% yield) and **9** (41% yield). These stereoisomes were separated by MPLC. The stereochemistry of each trisubstituted double bond was confirmed by the chemical shift value in ^1H NMR, already mentioned in the structural elucidation of **1** and **2**. Finally, deprotection of acetonide on the α-side chain in **8** followed by oxidative cleavage with $NaIO_4$ to remove the extra carbon provided **1** in 69% yield for two steps. The spectral data of synthetic **1** including the optical rotation {$[\alpha]_D^{25}$ −21.3° (*c* 0.04, $CHCl_3$)} were identical to those of natural **1**, thus indicating that the absolute stereochemistry at C-7 was confirmed as *S* configuration, the same as that of clavulones. Stereoisomer **2** was also synthesized similarly from **9** in 77% yield for two steps {$[\alpha]_D^{25}$ −49.3° (*c* 0.28, $CHCl_3$)}, concluding the *S* configuration.

The structural similarity of clavirins to clavulones, including the absolute stereochemistry, suggested the biosynthesis of clavirins derived from clavulones. A possible biogenetic pathway is shown in Fig. 2. Oxidative fragmentation between C-5 and C-6 for clavulone III and/or IV provides clavirin I (**1**), and clavulone I and/or II affords clavirin II (**2**). We are now seeking the related prostanoids from *C. viridis* to reinforce this biogenesis.



Figure 2.

Acknowledgements

The authors express their appreciation to Dr. Hideyo Yasuda and Dr. Reiko Honda at the Tokyo University of Pharmacy and Life Science for performing the bioassay, and Dr. Yasuo Shida at the Tokyo University of Pharmacy and Life Science for measurements of mass spectra. This work was supported

by Grant-in-Aid for Scientific Research (09680575) from the Ministry of Education, Science, Sports and Culture of Japan.

References

1. (a) Kikuchi, H.; Tsukitani, Y.; Iguchi, K.; Yamada, Y. *Tetrahedron Lett.* **1982**, *23*, 5171. (b) Kikuchi, H.; Tsukitani, Y.; Iguchi, K.; Yamada, Y. *Tetrahedron Lett.* **1983**, *24*, 1549. (c) Nagaoka, H.; Miyakoshi, T.; Yamada, Y. *Tetrahedron Lett.* **1984**, *25*, 3621.
2. (a) Kobayashi, M.; Lee, N. K.; Son, B. W.; Yanagi, K.; Kyogoku, Y.; Kitagawa, I. *Tetrahedron Lett.* **1984**, *25*, 5925. (b) Iguchi, K.; Iwashima, M.; Watanabe, K. *Chem. Lett.* **1995**, 1109.
3. (a) Iwashima, M.; Watanabe, K.; Iguchi, K. *Tetrahedron Lett.* **1997**, *38*, 8319. (b) Iwashima, M.; Okamoto, K.; Konno, F.; Iguchi, K. *J. Nat. Prod.* **1999**, *62*, 352. (c) Iwashima, M.; Okamoto, K.; Miyai, Y.; Iguchi, K. *Chem. Pharm. Bull.* **1999**, *47*, 884.
4. Gerwick, W. H. *Chem. Rev.* **1993**, *93*, 1807.
5. (a) Iguchi, K.; Kaneta, S.; Mori, K.; Yamada, Y.; Honda, A.; Mori, Y. *Tetrahedron Lett.* **1985**, *26*, 5787. (b) Nagaoka, H.; Iguchi, K.; Miyakoshi, T.; Yamada, N.; Yamada, Y. *Tetrahedron Lett.* **1986**, *27*, 223.
6. Zhu, J.; Yang, J.-Y.; Klunder, A. J. H.; Liu, Z.-Y.; Zwanenburg, B. *Tetrahedron* **1995**, *51*, 5847.
7. Stork, G.; Isobe, M. *J. Am. Chem. Soc.* **1975**, *97*, 6260.
8. Compound **7**: $[\alpha]_D$ −89.1° (*c* 0.44, $CHCl_3$); IR (film) 3417, 1713, 1674 cm^{-1}; ^1H NMR (400 MHz, δ ppm, *J* in hertz) 7.42 (1H, d, 5.7), 6.14 (1H, d, 5.7), 5.67 (1H, ddd, 10.7, 7.5, 7.3), 5.37 (1H, dt, 10.7, 7.6), 2.56 (1H, dd, 14.1, 7.5), 2.55 (1H, d, 18.2), 2.47 (1H, dd, 14.1, 7.3), 2.46 (1H, d, 18.2), 2.12 (1H, br s), 2.05 (2H, dt, 7.6, 7.1), 1.23–1.38 (6H, m), 0.88 (3H, t, 7.1); ^{13}C NMR (100 MHz, δ ppm) 206.5 (C), 165.2 (CH), 135.9 (CH), 133.8 (CH), 121.9 (CH), 78.7 (C), 48.6 (CH_2), 38.0 (CH_2), 31.5 (CH_2), 29.1 (CH_2), 27.4 (CH_2), 22.5 (CH_2), 14.0 (CH_3); FABMS *m/z* 209 $(M+H)^+$; Anal. calcd for $C_{13}H_{20}O_2$: C, 74.96; H, 9.68; found: C, 74.84; H, 9.68; previously reported **7**: $[\alpha]_D$ −54.1° (*c* 1.52, $CHCl_3$).[1c]